Headquarters: San Diego

CEO: Stephen Davis

August quarterly results: The company reported $57.1 million in revenue, an 87 percent year-over-year increase. Net loss was listed as $63.3 million.

Stock listing: ACAD on Nasdaq

Company description: Acadia’s Nuplazid was the first approved drug to treat hallucinations and delusions caused by Parkinson’s disease. The company is developing the drug for other indications.

Acadia Pharmaceuticals is flying higher after the U...

Take 1 minute to subscribe and you'll get this story immediately, plus:

Already a subscriber? Sign in

  • 52 weekly issues
  • Subscriber-only digital content every business day, plus full access to archives
  • Book of Lists — the most comprehensive business resource in San Diego
  • San Diego 500 — influential business leaders you need to know
Yours for only $129